Business
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resis
About this update from Monte Rosa Therapeutics, Inc.
[{"type":"image","alt":"Monte Rosa Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Monte Rosa Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OzxkCVdlx.rHq4uLVBRKVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c99f028be58427489eba79299e175651","width":300,"height":82}},"lazy":false},{"type":"text","content":"Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases","length":398,"tagName":"p"},{"type":"text","content":"Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; deprioritizing further expansion arms in SCLC, NSCLC and NE tumors ","length":362,"tagName":"p"},{"type":"text","content":"MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025","length":147,"tagName":"p"},{"type":"text","content":"Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts","length":122,"tagName":"p"},{"type":"text","content":"Company to host conference call and webcast today at 8:00 a.m. ET","length":65,"tagName":"p"},{"type":"text","content":"BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported a clinical update, business highlights, and financial results for the fourth quarter ended December 31, 2024.","length":316,"tagName":"p"},{"type":"text","content":"“We continue to make excellent progress with our clinical and preclinical mo...